Haemonetics (NYSE: HAE) net income
Haemonetics reported a net profit of $97.3m for fiscal 2026, 42.0% less than in fiscal 2025 ($167.7m). Its net margin was 7.3%. Earnings per share were $2.06.
Haemonetics's best year of the last 10 was fiscal 2025. The biggest drop was in fiscal 2022, −45.4%. It reported a loss in 1 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2026 | $97.3m | −42.0% | 7.3% | $2.06 |
| 2025 | $167.7m | +42.6% | 12.3% | $3.33 |
| 2024 | $117.6m | +1.9% | 9.0% | $2.32 |
| 2023 | $115.4m | +166.1% | 9.9% | $2.27 |
| 2022 | $43.4m | −45.4% | 4.4% | $0.85 |
| 2021 | $79.5m | +3.8% | 9.1% | $1.57 |
| 2020 | $76.5m | +39.1% | 7.7% | $1.51 |
| 2019 | $55.0m | +20.7% | 5.7% | $1.07 |
| 2018 | $45.6m | — | 5.0% | $0.86 |
| 2017 | −$26.3m | — | −3.0% | −$0.51 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Haemonetics net income compared with its sector
By net income for its latest fiscal year, Haemonetics ranks 114th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Haemonetics, 7.3%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 112th | Phibro Animal Health | $99.7m | 6.6% |
| 113th | Amphastar Pharmaceuticals | $98.1m | 13.6% |
| 114th | Haemonetics | $97.3m | 7.3% |
| 115th | Addus HomeCare | $95.9m | 6.7% |
| 116th | Embecta | $95.4m | 8.8% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Haemonetics
- How much did Haemonetics earn in fiscal 2026?
- Haemonetics reported a net profit of $97.3m for fiscal 2026. In fiscal 2025 it reported a net profit of $167.7m.
- What are the earnings per share of Haemonetics?
- They were $2.06 in fiscal 2026, compared with $3.33 in fiscal 2025.
- What is the net margin of Haemonetics?
- In fiscal 2026 its net profit was 7.3% of its revenue.
- What was the most profitable year for Haemonetics?
- Of its last 10 fiscal years, fiscal 2025, with $167.7m.
- Where does Haemonetics rank in its sector by net income?
- It ranks 114th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Haemonetics come from?
- From the annual report (Form 10-K) that Haemonetics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Haemonetics files with the SEC. The filing for each fiscal year: 2026 · 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017. More on Haemonetics: the Haemonetics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.